PEA, Federico; POZ, Donatella; BARALDO, Massimo; FURLANUT, Mario, Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function. Multiple daily doses may be preferable, «CLINICAL DRUG INVESTIGATION», 2000, 19, pp. 213 - 218 [Comment or similar]
Pea F.; Furlanut M.; Bianchi L., Systemic vancomycin overexposure in a patient with spinal cord injury who had staphylococcal sepsis and Clostridium difficile colitis, «THERAPEUTIC DRUG MONITORING», 2000, 22, pp. 233 - 234 [Comment or similar]
Baraldo M.; Ferraccioli G.; Pea F.; Gremese E.; Furlanut M., Cyclosporine a pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy, «PHARMACOLOGICAL RESEARCH», 1999, 40, pp. 483 - 486 [Scientific article]
Pea F.; Milaneschi R.; Baraldo M.; Talmassons G.; Furlanut M., Isoniazid and its hydrazine metabolite in patients with tuberculosis, «CLINICAL DRUG INVESTIGATION», 1999, 17, pp. 145 - 154 [Scientific article]
Michieli M.; Damiani D.; Ermacora A.; Masolini P.; Michelutti A.; Michelutti T.; Russo D.; Pea F.; Baccarani M., Liposome-encapsulated daunorubicin for PGP-related multidrug resistance, «BRITISH JOURNAL OF HAEMATOLOGY», 1999, 106, pp. 92 - 99 [Scientific article]
Pea F.; Damiani D.; Michieli M.; Ermacora A.; Baraldo M.; Russo D.; Fanin R.; Baccarani M.; Furlanut M., Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 1999, 55, pp. 361 - 368 [Scientific article]
Pea F.; Furlanut M.; Poz D.; Baraldo M., Pharmacokinetic profile of two different administration schemes of teicoplanin. Single 400 mg intravenous dose vs double-refracted 200 mg intramuscular doses in healthy volunteers, «CLINICAL DRUG INVESTIGATION», 1999, 18, pp. 47 - 55 [Scientific article]
Damiani D.; Michieli M.; Ermacora A.; Russo D.; Fanin R.; Zaja F.; Baraldo M.; Pea F.; Furlanut M.; Baccarani M., Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia, «LEUKEMIA», 1998, 12, pp. 1236 - 1240 [Scientific article]
Wu G.; Pea F.; Cossettini P.; Furlanut M., Effect of the number of samples on bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance, «JOURNAL OF PHARMACY AND PHARMACOLOGY», 1998, 50, pp. 343 - 349 [Scientific article]
Benetello P.; Furlanut M.; Fortunato M.; Pea F.; Baraldo M., Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association, «PHARMACOLOGICAL RESEARCH», 1997, 35, pp. 313 - 315 [Scientific article]
Benetello P.; Furlanut M.; Fortunato M.; Baraldo M.; Pea F.; Tognon A.; Testa G., Oral gabapentin disposition in patients with epilepsy after a high- protein meal, «EPILEPSIA», 1997, 38, pp. 1140 - 1142 [Scientific article]
Furlanut M.; Baraldo M.; Pea F.; Marzocchi V.; Croattino L.; Galla F., Blood concentrations and clinical effect of cyclosporin in psoriasis, «THERAPEUTIC DRUG MONITORING», 1996, 18, pp. 544 - 548 [Scientific article]
Furlanut M.; Baraldo M.; Galla F.; Marzocchi V.; Pea F., Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis, «PHARMACOLOGICAL RESEARCH», 1996, 33, pp. 349 - 352 [Scientific article]
Wu G.; Baraldo M.; Pea F.; Cossettini P.; Furlanut M., Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by bayesian and non-linear least squares methods, «PHARMACOLOGICAL RESEARCH», 1995, 32, pp. 355 - 362 [Scientific article]
DAMIANI, D; MICHIELI, M; MICHELUTTI, A; PEA, F; BARALDO, M; FANIN, R; RUSSO, D; FURLANUT, M; BACCARANI, M, P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases, «LEUKEMIA», 1995, 9, pp. 1792 - 1795 [Comment or similar]
